Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis

Arthritis and Rheumatism

Volumn 46, Issue 7, 2002, Pages 1926-1936

  Campagnuolo, Giuseppe ^a   Bolon, Brad ^a   Feige, Ulrich ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; OSTEOPROTEGERIN; PROTEOGLYCAN; TOLONIUM CHLORIDE;

ABSORPTIOMETRY; ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; BONE DENSITY; BONE EROSION; BONE INJURY; BONE MINERAL; CARTILAGE MATRIX; CELL ASSAY; CONTROLLED STUDY; DISEASE COURSE; DISSOLUTION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; EDEMA; GENDER; HISTOPATHOLOGY; INFLAMMATION; KINETICS; MALE; NONHUMAN; OSTEOCLAST; OSTEOPHYTE; OSTEOPOROSIS; PERIOSTEUM; PRIORITY JOURNAL; PROTECTION; RAT; RAT STRAIN; SCORING SYSTEM; TISSUE SECTION; TREATMENT INDICATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE DENSITY; CARTILAGE, ARTICULAR; DENSITOMETRY, X-RAY; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GLYCOPROTEINS; MALE; OSTEOCLASTS; OSTEOPROTEGERIN; RATS; RATS, INBRED LEW; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS;

EID: 0036068297     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10369     Document Type: Article

References (54)

1. The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption
2. Osteoprotegerin and receptor activator of nuclear factor κ B ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint
3. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
4. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
5. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
6. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
7. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
8. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
9. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
10. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
11. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis
12. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
13. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
14. Fc-osteoprotegerin fusion protein (Fc-OPG) reduces osteoclast numbers and prevents bone destruction in rats with collageninduced arthritis
15. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis
16. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis
17. The effect of a single dose of osteoprotegerin in postmenopausal women
18. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint
19. Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis
20. A new mechanism of bone destruction in rheumatoid arthritis: Synovial fibroblasts induce osteoclastogenesis
21. Abnormal bone remodelling in inflammatory arthritis
22. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis
23. Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover
24. Osteoclast-like cells in murine collagen induced arthritis
25. Changes in location and number of tartrate-resistant acid phosphatase (TRAP)-positive cells during the development of type II collagen-induced arthritis in DBA/1J mice
26. IL-1ra and PEG sTNF-RI reduce osteoclast numbers in rats with adjuvant arthritis
27. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis
28. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function
29. Expression of osteoclast differentiation factor in rheumatoid arthritis
30. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis
31. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: Receptor activator of NF-κB ligand
32. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis
33. Human osteoclast formation from blood monocytes, peritoneal macrophages, and bone marrow cells
34. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis
35. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent
36. Osteoclast lineage commitment of bone marrow precursors through expression of membrane-bound TRANCE
37. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
38. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclasts
39. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo
40. Anti-interleukin-1 and anti-tumor necrosis factor-α synergistically inhibit adjuvant arthritis in Lewis rats
41. Preferred sites and measurements for rapid osteoclast quantification in rat adjuvant arthritis
42. Osteoprotegerin
43. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo
44. Osteoclastogenesis in iliac bone marrow of patients with rheumatoid arthritis
45. Role of pro-inflammatory cytokines in rheumatoid arthritis
46. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
47. Comparison of etanercept vs. methotrexate in early rheumatoid arthritis using gadolinium-enhanced magnetic resonance imaging
48. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: Implications for the role of cytokines in cartilage destruction and repair
49. Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis
50. Activated T lymphocytes support osteoclast formation in vitro
51. Osteoclasts in normal and adjuvant arthritis bone tissues express the mRNA for both type I and II interleukin-1 receptors
52. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
53. Tumor necrosis factor-α (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways
54. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis